Causes of death in patients (pts) with acute myelogenous lukemia (AML) and high-risk myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC).

被引：0
|
作者：
Mattiuzzi, GN [1 ]
Alvarado, G [1 ]
Alvarez, R [1 ]
Pierce, S [1 ]
Cortes, J [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
Faderl, S [1 ]
Estey, E [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3267
引用
收藏
页码：878A / 878A
页数：1
相关论文
共 50 条
  • [1] Causes of pneumonia (pn) in patients (pts) with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC).
    Mattiuzzi, G
    Pierce, S
    Faderl, S
    Cortes, J
    Koller, C
    Estey, E
    [J]. BLOOD, 2000, 96 (11) : 324A - 324A
  • [2] Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts
    Mattiuzzi, Gloria
    Kantarjian, Hagop
    Ho, Jennifer
    Garcia-Manero, Guillermo
    Cortes, Jorge
    [J]. BLOOD, 2009, 114 (22) : 1206 - 1206
  • [3] Acute myelogenous leukemia (AML) type induction chemotherapy for the patients with myelodysplastic syndrome (MDS)
    Kim, D.-Y.
    Kim, J.-S.
    Kim, B.-S.
    Bang, S.-M.
    Kim, I.
    Yoon, S.-S.
    Park, S.
    Kim, B. K.
    [J]. LEUKEMIA RESEARCH, 2007, 31 : S138 - S138
  • [4] Intravenous itraconazole (ITRA) versus caspofungin (CASPO) for prophylaxis of invasive fungal infections (IFI) in patients (PTS) with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC).
    Mattiuzzi, GN
    Riehl, TD
    Pierce, SR
    Rex, JH
    Cortes, JE
    Giles, FJ
    Garcia-Manero, G
    Verstovsek, S
    Malekshamran, K
    Kantarjian, HM
    Estey, EH
    [J]. BLOOD, 2002, 100 (11) : 332A - 332A
  • [5] Double induction (DI) chemotherapy for patients (pts) with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).
    Garcia-Manero, G
    Faderl, S
    Giles, F
    Verstovsek, S
    Beran, M
    Andreeff, M
    Cortes, J
    Thomas, D
    Koller, C
    Pierce, S
    Ouzonian, S
    Kantarjian, H
    Estey, E
    [J]. BLOOD, 2002, 100 (11) : 342A - 342A
  • [6] An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).
    Mattiuzzi, Gloria
    Lahoti, Amit
    Salahudeen, Abdulla
    Ravandi, Farhad
    Cortes, Jorge
    Vu, Khanh
    Kantarjian, Hagop
    [J]. BLOOD, 2009, 114 (22) : 419 - 420
  • [7] Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy
    Mattiuzzi, GN
    Kantarjian, H
    O'Brien, S
    Kontoyiannis, DP
    Giles, F
    Zhou, X
    Lim, J
    Bekele, BN
    Faderl, S
    Cortes, J
    Pierce, S
    Leitz, GJ
    Raad, I
    Estey, E
    [J]. CANCER, 2004, 100 (03) : 568 - 573
  • [8] Intravenous voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Mattiuzzi, GN
    Alvarado, G
    Kantarjian, HM
    Verstovsek, S
    Cabanillas, M
    Faderl, S
    Lim, JT
    Giles, F
    Beran, M
    O'Brien, S
    Estey, EH
    [J]. BLOOD, 2004, 104 (11) : 253A - 253A
  • [9] Azatidine Treatment in Very Elderly Patients Diagnosed with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
    Gutierrez, Javier
    Morales, Elena
    Gonzalez, Matilde
    Herrada, Juan
    [J]. BLOOD, 2015, 126 (23)
  • [10] Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Chen, Y.
    Kantarjian, H.
    Garcia-Manero, G.
    Estrov, Z.
    Konopleva, M.
    Jabbour, E.
    Kadia, T. M.
    Williams, E.
    George, S.
    Borthakur, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345